Biosensors extends licensing agreement with Terumo

The agreement involves the BioMatrix™ technology.

Biosensors International Group, Ltd. and Terumo Corporation announced an extension of their existing licensing agreements in markets worldwide, outside of the United States. Terumo may continue incorporating BioMatrix™ technology in the production, marketing, and selling of its drug‐eluting stent systems globally.

The two have agreed to extend the original licensing agreement for territories outside of Japan until December 2014, under terms similar to the original October 2003 agreement. Terumo also continues to benefit from its existing rights in Japan to manufacture, market, and sell DES systems incorporating BioMatrix® technology.

Under the original agreements, Terumo began introducing its Nobori™ DES system in global markets outside of Japan and the United States in 2008, and in Japan in 2011.

Nobori is now sold in over 20 countries across Europe, Asia, and Latin America. It incorporates both Biolimus A9™, an anti‐restenotic drug developed and patented by Biosensors specifically for use with stents, as well as Biosensors’ unique abluminal biodegradable polymer coating.